MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS

INTRODUCTION: Activation of the RAS-MAPK signaling cascade is common in pediatric gliomas. Based on the role of SHP2 in RAS pathway signaling, we hypothesized that NF1-deficient pediatric glioma models would respond to SHP2 inhibitor monotherapy whereas BRAF-V600E gliomas would not. However, we post...

Descripción completa

Detalles Bibliográficos
Autores principales: Muldoon, Daniel, Zhao, Guisheng, Batt, Carly, Singh, Mallika, Nicolaides, Theodore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Preclinical Models/Experimental Therapy/Drug Discovery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715749/
http://dx.doi.org/10.1093/neuonc/noaa222.591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715749/
http://dx.doi.org/10.1093/neuonc/noaa222.591

Ejemplares similares